Clinical trials · Washington, D.C., DC
Malignant Female Reproductive System Neoplasm clinical trials in Washington, D.C.
We’re tracking 8 recruiting malignant female reproductive system neoplasm studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Washington D.C., District of ColumbiaAges 1–30 - NCT06513962RecruitingPhase 3
Triptorelin to protect ovaries in young women with cancer
This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.
Washington D.C., District of ColumbiaAges Up to 39 years - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Washington D.C., District of ColumbiaAges 1–30 - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Bethesda, MarylandAges Any age - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Bethesda, MarylandAges 18 years+ - NCT03968406RecruitingPhase 1
Talazoparib plus radiation for recurrent gynecologic cancers
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
Baltimore, MarylandAges 18 years+
Hear when a new Malignant Female Reproductive System Neoplasm trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Malignant Female Reproductive System Neoplasm trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting malignant female reproductive system neoplasm studies listed above.
- Children's National Medical Center · 4 studies
- National Institutes of Health Clinical Center · 3 studies
- Walter Reed National Military Medical Center · 3 studies
- Inova Fairfax Medical Campus · 2 studies
- Inova Schar Cancer Institute · 2 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 2 studies
- National Cancer Institute (NCI)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
What taking part in a malignant female reproductive system neoplasm study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there malignant female reproductive system neoplasm clinical trials near Washington, D.C.?
- Yes. We're currently tracking 8 recruiting malignant female reproductive system neoplasm studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a malignant female reproductive system neoplasm study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a malignant female reproductive system neoplasm trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New malignant female reproductive system neoplasm studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.